Member Info for JoeyDiamond

Hi HelloSanDiego, I am talking about P3 trials, for example SNG and Regeneron had around 4% in placebo.

Regeneron results
Covid-19–related hospitalization or death from any cause occurred in 18 of 1355 patients in the REGEN-COV 2400-mg group (1.3%) and in 62 of 1341 patients in the placebo group who underwent randomization concurrently (4.6%)

https://www.nejm.org/doi/full/10.1056/NEJMoa2108163

14% for Mercks drug vs 4.6% in Regenerons P3 trial. Why in Mercks case was there such a huge difference in placebo compared to its peers?

The first half of the original Merck trial had very dubious data, 14% hospitalisation in placebo arm is just one example (Most other trials it was on average 4%). Placebo and Drug arms were not well matched when it came to patient comorbidities. The irregularities were well documented by many at the time.

The trial was ended early by Merck as in the 2nd half of the trial (trialled in other countries other than Brazil) the drug actually had negative efficacy. Merck knew if they kept recruiting the efficacy of the drug would keep dropping hence trial stopped early.

Many of us sounded the alarm on the original trial that it wasn't trustworthy and this new trial has confirmed our fears.

I agree EUA needs to be revoked immediately considering how the drug is mutagenic and is now causing more harm than good overall.

https://mobile.twitter.com/EricTopol/status/1578220417029767168

New on Molnupiravir
A randomized trial of ~26,000 patients with Covid, mean age 57 with 2 days of symptoms, showed no difference in hospitalizations or deaths, the primary endpoint, compared with usual care.

I said during the trials there were glaring issues and there was out right fraud going on. If I could see it how on earth could the FDA not! Sadly more evidence the FDA is captured by big pharma.

https://ir.eigerbio.com/news-releases/news-release-details/eiger-biopharmaceuticals-provides-update-plans-emergency-use

No EUA for peginterferon lambda. Surprising considering it had better results than some of the current drugs that have an existing EUA.

William Fischer, M.D., University of North Carolina (UNC), a lead investigator of SNG001 said: "These results, including a decrease in hospitalisations and adverse events among participants who received SNG001, are promising and warrant further investigation in a larger Phase 3 clinical trial.

Chances of making STRIVE have increased.

Good results and shows why SNG originally progressed to Phase 3 stage of the trial.

Very likely there is a statistical significant result once age stratification is applied. Ie if we look at only over 60s in the trial.

With regards to vaccines if you are getting a booster, a bivalent vaccine with WT / BA.5 is better than the standard UK offering of the bivalent vaccine with WT / BA.1.

Not sure if you get to choose what one you get but one that protects against BA.5 gives better protection against BQ.1.1

https://mobile.twitter.com/yunlong_cao/status/1573391234118610944

As expected, BQ.1.1 escapes Evusheld and bebtelovimab, making all clinically available antibody drugs ineffective.

https://mobile.twitter.com/CorneliusRoemer/status/1576716682512388096

Data now showing what the dominant variant will be for the next Covid wave

Most Western countries have announced Covid is over including the USA recently, so politically funding new platform trials is very unlikely. At least until after the midterms in November, Dems may change stance when votes are no longer required and a winter covid wave hits.

I think SNG strategy is to wait for this winter in the hope for a platform trial, failing this as the RNS + interview alludes to they are now vocally saying a company led trial is a possibility.

Basically a waiting game.

What no Katie!

Suggest people actually read the RNS, standard practice they tell you if they have cash for the next 12 months in the outlook.

'Group's available resources are sufficient to cover existing committed costs and the costs of these activities until at least 30 September 2023.'

This doesn't mean they run out of cash at this date.

November 14/15th would be my expectation.

Be fair Tommy they tested it on 8 mice before approving.

https://stimulate-icp.org/care

This is the trial you are talking about. The following drugs are proposed at the outset to be trialled, more may be added.

Famotidine/Loratidine: Patients with long COVID may have persistent inflammation, which is related to “mast cell activation” and release of histamine. Famotidine and loratadine are histamine receptor blockers which are commonly used to treat mast-cell activation in other conditions. In long COVID, antihistamines have been of benefit in some patients.

Rivaroxaban: People with long COVID may have “micro-clots” in their circulation. These clots could reduce oxygen reaching large muscles during exercise, possibly explaining the “post-exertional malaise” which people with long COVID often describe. There are increasing reports from patients and their health professionals of success of therapy with anti-clotting drugs such as rivaroxaban.

Colchicine: In some patients with long COVID, there is inflammation around the lining of the heart (“pericarditis”) and lungs (“pleuritis”). Colchicine is an anti-inflammatory drug which has benefit in pericarditis. Given the high proportion of people with long COVID who have chest pain and breathlessness, pericarditis and pleuritis are likely to be common, and colchicine may be of benefit.

And something really cool

https://mobile.twitter.com/jbloom_lab/status/1572373222888460290

The #SARSCoV2 RBD antibody escape calculator

https://www.biorxiv.org/content/10.1101/2022.09.15.507787v1

Another worrying study on these newer variants. Both natural immunity and vaccines won’t be enough. I would expect another Covid wave in the coming months.

Fruitsnveg yes you have posted the key takeaway from the paper which im surprised no one else on the board has clocked.

'it effectively evades current humoral immunity in the population' should be highlighted in bold.

People are going to need to their innate immunity to be in tip top shape.

And if you fancy a read of useful studies and the likely direction of Covid then a good thread here

https://mobile.twitter.com/EllingUlrich/status/1571051885506985984

https://mobile.twitter.com/BenjMurrell/status/1570862185819303937

BA.2.75.2 exhibits more extreme antibody escape than any variant we've seen so far. Not the best news for existing drugs and vaccines.